|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500108566 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-01 17:50:06 |
|
注册时间: Date of Registration: |
2025-09-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
慢性阻塞性肺疾病患者下尿路症状的超声影像尿动力学特征及机制研究 |
|
Public title: |
The research of character and mechnism in patients with lower urinary tract symptoms complicated with chronic obstructive pulmonary diseases using sonography videourodynamic studies |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
慢性阻塞性肺疾病患者下尿路症状的超声影像尿动力学特征及机制研究 |
|
Scientific title: |
The research of character and mechnism in patients with lower urinary tract symptoms complicated with chronic obstructive pulmonary diseases using sonography videourodynamic studies |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
肖宁 |
研究负责人: |
肖宁 |
|
Applicant: |
Ning Xiao |
Study leader: |
Ning Xiao |
|
申请注册联系人电话: Applicant telephone: |
+86 189 7599 5608 |
研究负责人电话: Study leader's telephone: |
+86 189 7599 5608 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xy20001816@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xy20001816@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广西桂林市临桂区人民路212号 |
研究负责人通讯地址: |
广西桂林市临桂区人民路212号 |
|
Applicant address: |
212 Renmin Road, Lingui District, Guilin, Guangxi |
Study leader's address: |
212 Renmin Road, Lingui District, Guilin, Guangxi |
|
申请注册联系人邮政编码: Applicant postcode: |
541199 |
研究负责人邮政编码: Study leader's postcode: |
541199 |
|
申请人所在单位: |
桂林医学院第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Guilin Medical University |
||
|
研究负责人所在单位: |
桂林医学院第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Guilin Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
ZLXM-2025025 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
桂林医学院第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of the Second Affiliated Hospital of Guilin Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-03 00:00:00 |
||
|
伦理委员会联系人: |
候显良 |
||
|
Contact Name of the ethic committee: |
Xianliang Hou |
||
|
伦理委员会联系地址: |
广西桂林市临桂区人民路212号 |
||
|
Contact Address of the ethic committee: |
212 Renmin Road, Lingui District, Guilin, Guangxi |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 181 7836 9829 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
efyky@glmc.edu.cn |
|
研究实施负责(组长)单位: |
桂林医学院第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Guilin Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广西桂林市临桂区人民路212号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
212 Renmin Road, Lingui District, Guilin, Guangxi |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||
|
Target disease: |
lower urinary tract symptoms; chronic obstructive pulmonary diseases |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
慢性阻塞性肺疾病(COPD)发病率高,特别在男性吸烟者更为严重。既往研究发现,合并COPD患者下尿路症状(LUTS)更为常见,然而并无相关尿动学特征的研究报道。因此,我们将回顾性研究在我院因LUTS行超声影像尿动力学检查(SVUDS)COPD患者的临床资料,分析SVUDS特征及探索可能的发病机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
The incidence of chronic obstructive pulmonary disease (COPD) is high, especially more severe in male smokers. Previous studies have found that patients with COPD have more frequent lower urinary tract symptoms (LUTS). However, there have been no reports on related urodynamic characteristics. Therefore, we will conduct a retrospective study to review the clinical data of COPD patients who underwent ultrasound imaging urodynamic examination (SVUDS) for LUTS in our hospital, analyze the characteristics of SVUDS and explore the possible pathogenesis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.基础疾病确诊要求:符合《中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年)》诊断标准:①支气管舒张剂后FEV1/FVC<0.7;②存在持续性咳嗽、咳痰或呼吸困难症状;③有吸烟史(≥10包年)或长期有害气体暴露史;④COPD临床分期为GOLD 2-4级(中度至极重度) 2.下尿路症状标准:①国际前列腺症状评分(IPSS)≥8分;②持续存在以下至少1项症状≥3个月:③储尿期症状:尿频(日间≥8次)、尿急、夜尿(≥2次/晚);④排尿期症状:尿流细弱、排尿踌躇、间断排尿;⑤排尿后症状:尿不尽感 3.影像尿动力学检查要求:①超声显示膀胱残余尿量(PVR)≥50ml;②尿流率测定Qmax<15ml/s(尿量≥150ml时) |
||||||||||||||||||||||
|
Inclusion criteria |
1. Requirements for diagnosing underlying diseases: Must meet the diagnostic criteria of the "Guidelines for Basic Diagnosis and Management of Chronic Obstructive Pulmonary Disease in China (2024)": (1) FEV1/FVC after bronchodilator is less than 0.7; (2) Persistent cough, expectoration or breathing difficulty symptoms; (3) Smoking history (>= 10 pack-years) or long-term exposure to harmful gases; (4) COPD clinical stage is GOLD 2-4 (moderate to severe). 2. Criteria for lower urinary tract symptoms: (1) International Prostate Symptom Score (IPSS) >= 8 points; (2) Persistent presence of at least one of the following symptoms for >= 3 months: (3) Storage phase symptoms: frequent urination (>= 8 times per day), urgency, nocturia (>= 2 times per night); (4) Urination phase symptoms: weak urine flow, hesitation in urination, intermittent urination; (5) Post-urination symptoms: incomplete urination sensation. 3. Requirements for imaging and urodynamic examinations: (1) Ultrasound shows residual urine volume in the bladder (PVR) >= 50 ml; (2) Urinary flow rate measurement Qmax < 15 ml/s (when urine volume >= 150 ml). |
||||||||||||||||||||||
|
排除标准: |
1.有明确神经系统病史,精神失常者,糖尿病史患者。 2.诊断为神经源性膀胱患者。 3.伴有尿道狭窄或尿道损伤史患者。 4.脊柱损伤、盆腔神经损伤、盆腔手术史放疗病史患者。 5.前列腺癌、膀胱肿瘤、盆腔占位性病变、腹腔积液等其他影响逼尿肌压力者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those with a clear history of neurological disorders, mental disorders, and diabetes patients. 2. Patients diagnosed with neurogenic bladder. 3. Patients with a history of urethral stricture or urethral injury. 4. Patients with spinal cord injury, pelvic nerve injury, pelvic surgery history, radiotherapy history. 5. Patients with prostate cancer, bladder tumor, pelvic space-occupying lesion, ascites in abdominal cavity, and other conditions that affect the detrusor muscle pressure. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-09-30 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |